The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The Chronic Idiopathic Urticaria Treatment Market?

The chronic idiopathic urticaria treatment market size has seen significant growth in recent years. It is anticipated to expand from $7.24 billion in 2025 to $7.89 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.0%. This historical growth can be attributed to an increased diagnosis of chronic urticaria, the availability of second-line antihistamine therapies, the adoption of stepwise treatment protocols, the expansion of allergy specialty clinics, and the growing use of immunomodulatory drugs.

The chronic idiopathic urticaria treatment market is projected to experience robust expansion over the coming years. This market is set to reach $11.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.2%. Factors contributing to this growth during the forecast period include a heightened demand for biologic therapies, an increased emphasis on individualized immunology care, the proliferation of digital tools for disease management, greater investment in new urticaria treatments, and improved patient understanding and compliance with therapy. Key trends anticipated for this period encompass a wider acceptance of biologic therapies for individuals with difficult-to-treat conditions, a surge in the implementation of tailored treatment plans, increased incorporation of digital tools for symptom tracking, an expansion of available injectable medications, and a stronger emphasis on managing the disease over the long term.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33064&type=smp

Which Growth Drivers Are Expected To Support The Chronic Idiopathic Urticaria Treatment Market Forward?

An escalating emphasis on biologics is anticipated to stimulate the expansion of the chronic idiopathic urticaria treatment market moving forward. Biologics are therapeutic products derived from living organisms or their constituents, designed to target specific immune system pathways for treating diseases. The growing focus on biologics is attributed to advancements in biotechnology and immunology, which have facilitated the creation of more precise and effective treatments that address the underlying mechanisms of immune-mediated conditions, rather than merely managing symptoms. These biologics specifically target the fundamental immune pathways and mast cell activation responsible for chronic idiopathic urticaria, thus transforming treatment approaches and offering patients more effective and durable symptom control. For example, in February 2025, the World Health Organization (WHO), a Switzerland-based intergovernmental body, stated that its 2023 Essential Medicines List comprises 81 biologic therapies, constituting over 15% of all listed medicines. Therefore, the heightened focus on biologics is propelling the growth of the chronic idiopathic urticaria treatment market.

How Is The Chronic Idiopathic Urticaria Treatment Market Structured Across Different Market Segments?

The chronic idiopathic urticaria treatment market covered in this report is segmented –

1) By Types: Tablets; Capsules; Creams; Lotions; Injections

2) By Drug Class: Antihistamines; Corticosteroids; Leukotriene Receptor Antagonists; Immunosuppressants; Biologic Therapies; Other Drug Class

3) By Route Of Administration: Oral; Injectable; Topical

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Tablets: Immediate Release Tablets; Extended Release Tablets; Enteric Coated Tablets; Chewable Tablets; Orally Disintegrating Tablets

2) By Capsules: Hard Gelatin Capsules; Soft Gelatin Capsules; Sustained Release Capsules; Delayed Release Capsules

3) By Creams: Medicated Topical Creams; Anti Inflammatory Creams; Antifungal Creams; Antibacterial Creams; Moisturizing Therapeutic Creams

4) By Lotions: Medicated Therapeutic Lotions; Anti Inflammatory Lotions; Antiseptic Lotions; Moisturizing Lotions; Specialty Dermatological Lotions

5) By Injections: Intravenous Injections; Intramuscular Injections; Subcutaneous Injections; Pre Filled Syringe Injections; Auto Injector Based Injections

What Trends Are Influencing The Chronic Idiopathic Urticaria Treatment Market?

Leading companies in the chronic idiopathic urticaria treatment market are concentrating on developing innovative products, such as monoclonal antibody therapies, to offer targeted, lasting relief for patients who do not respond to conventional treatments. These monoclonal antibody therapies are biologic medications specifically engineered to target immune system components, like immunoglobulin E (IgE) or other inflammatory mediators that cause chronic hives, thereby providing more precise action compared to traditional antihistamines or corticosteroids. For example, in September 2025, Celltrion Inc., a biopharmaceutical company based in South Korea, introduced Omriclo, an omalizumab biosimilar, in Norway. This product contains the same active monoclonal antibody as Xolair, works by neutralizing circulating IgE, and is administered via subcutaneous injection. Its distinctive characteristics include its first-mover status in Europe, improved accessibility via local distribution channels, and potential cost efficiencies for healthcare systems. It is intended for chronic idiopathic urticaria patients who remain symptomatic despite standard therapy, serving as a biologic alternative to conventional treatments, offering enhanced symptom management, reducing the frequency of flare-ups, and potentially improving overall quality of life by decreasing dependence on long-term antihistamine or corticosteroid use.

Which Organizations Are Involved In The Chronic Idiopathic Urticaria Treatment Market?

Major companies operating in the chronic idiopathic urticaria treatment market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG., AstraZeneca PLC, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Celltrion Inc., Yuhan Corporation, Kiniksa Pharmaceuticals Ltd., Celldex Therapeutics Inc., Septerna Therapeutics Inc., Carna Biosciences Inc., United BioPharma Inc., Recludix Pharma Inc., Jasper Therapeutics Inc., Evommune Inc., ARS Pharmaceuticals Inc

Access The Complete Chronic Idiopathic Urticaria Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/chronic-idiopathic-urticaria-treatment-market-report

Which Region Holds The Largest Share In The Chronic Idiopathic Urticaria Treatment Market?

North America was the largest region in the chronic idiopathic urticaria treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic idiopathic urticaria treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Chronic Idiopathic Urticaria Treatment Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model